Zynex organizacji EBITDA
Jaka jest wartość EBITDA organizacji Zynex?
Wartość EBITDA organizacji Zynex, Inc. to $27.296M
Jaka jest definicja EBITDA?
EBITDA to zysk firmy przed odliczeniem odsetek, podatków, amortyzacji i jest miarą księgową obliczoną na podstawie zarobków netto firmy, przed odliczeniem kosztów odsetek, podatków, amortyzacji i odliczeniem, jako wskaźnika bieżącej rentowności operacyjnej spółki.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA firm w Health Care sektor na HKSE w porównaniu do Zynex
Czym się zajmuję organizacja Zynex?
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Firmy z ebitda podobne do Zynex
- Wartość EBITDA organizacji BBX Capital to $27.168M
- Wartość EBITDA organizacji Sword SE to €27.170M
- Wartość EBITDA organizacji MiX Telematics Ltd to $27.174M
- Wartość EBITDA organizacji Andrews Sykes plc to £27.198M
- Wartość EBITDA organizacji Premier Miton plc to £27.199M
- Wartość EBITDA organizacji Computer Modelling to CAD$27.215M
- Wartość EBITDA organizacji Zynex to $27.296M
- Wartość EBITDA organizacji Antioquia Gold to CAD$27.336M
- Wartość EBITDA organizacji C & F Corp to $27.338M
- Wartość EBITDA organizacji Tongfang Kontafarma to HKD$27.343M
- Wartość EBITDA organizacji Artivion Inc to $27.349M
- Wartość EBITDA organizacji Zhong Hua International to HKD$27.350M
- Wartość EBITDA organizacji IM+ Capitals to ₨27.360M